Opexa Therapeutics: Personalized Immunotherapy For MS
Edison | Nov 30, 2015 07:20AM ET
Personalized immunotherapy for MS
Opexa’s Tcelna immunotherapy is advancing in Phase IIb studies in secondary progressive MS (SPMS), with data expected in H216. The firm is fully funded to Phase II data which, if positive, could sharply increase investor and stakeholder interest. Merck KGaA (N:MRK) has an option to in-license Tcelna in MS. Opexa (O:OPXA) is also developing OPX-212 in neuromyelitis optica (NMO), a rare autoimmune disorder leading to vision loss and paralysis. Opexa plans to file an IND and start a Phase I/II study in H116. Our rNPVderived equity valuation is $51m.
ImmPath aims to suppress autoimmune responses
Opexa’s core platform, ImmPath, produces patient-specific (autologous) T-cell immunotherapy following the collection of a patient’s own blood. The blood cells are screened against predefined potential self-reacting (autoimmune) target proteins, and the dominant self-reacting T-cell lines are isolated and expanded. An attenuated end-product is reinjected into the patient, which aims to suppress these undesired self-reacting T-cells and thus curb autoimmune disease progression.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.